Wyeth

Oscient Pharmaceuticals Corporation

Janssen Research & Development, LLC

Matthew Olson

Martin Di Grandi

Kristina Allen

Matthew J Todd

Amarnauth Shastrie Prashad

Anthony Anisowicz

Girija Krishnamurthy

Wei Chen

A method of screening a compound which modulates dipeptidyl peptidase I (DPPI) activities comprises the steps of adding a peptide substrate of DPPI to a reaction mixture which comprises DPPI and a compound, wherein the peptide substrate of DPPI has at least 3 amino acids and binds to a binding site of DPPI in addition to the S-Ssite; and measuring the molecular weight of the substrate, wherein a change in the molecular weight of the substrate is indicative of the presence of DPPI activity.

High-throughput assay for evaluating dipeptidyl peptidase I activity

The invention relates to a novel method of inexpensively synthesizing large quantities of an essentially pure, biologically active, glycosylated Dkk protein, including mammalian and human Dkk proteins (e.g., human Dkk1). The invention further relates to the synthetically produced essentially purified, glycosylated and biologically active Dkk protein, and the characteristics of the protein.

Method of synthesizing and purifying Dkk proteins and Dkk proteins obtained thereby

The present invention is directed to compounds of formula (I): wherein R, Rand Rare independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl and Xand Xare independently a bond or an linker group of 1 to 6 atoms and may be optional substituted or oxidized, or a prodrug, a pharmaceutically acceptable salt or a pharmaceutically active metabolite thereof. The invention is also directed to methods of using the same for treating HIV infections, or AIDs or preventing viral replication.

Triazole derivatives and method of using the same to treat HIV infections

The present invention is directed to compound of formula (A): 

Growing community of inventors

Spring City, PA, United States of America

Matthew Olson